Lapadula G
DIMIMP, Sezione di Reumatologia, Università degli Studi di Bari, Italia.
Reumatismo. 2005;57(4 Suppl):22-9. doi: 10.4081/reumatismo.2005.4s.22.
To evaluate the efficacy of the anti-TNFα (Tumor Necrosis Factor alpha) drugs in a variety of pathologic conditions such as psoriatic arthritis, undifferentiated entheso-arthritides, chronic inflammatory bowel diseases, adult onset Still's disease, Behcet disease.
Review of all published studies evaluating the efficacy of these drugs (mainly infliximab and etanercept, adalimumab to a lesser degree) on the above diseases.
Results are reported for each pathologic condition. Both drugs showed to be very efficacious in all the above conditions, except Crohn disease where etanercept does not seem adequate.
Both drugs work extremely well, even though comparison between infliximab and etanercept efficacy cannot be performed, due to the lack of a direct comparison.
评估抗TNFα（肿瘤坏死因子α）药物在多种病理状况下的疗效，如银屑病关节炎、未分化附着点关节炎、慢性炎症性肠病、成人斯蒂尔病、白塞病。
回顾所有已发表的评估这些药物（主要是英夫利昔单抗和依那西普，阿达木单抗程度较轻）对上述疾病疗效的研究。
报告了每种病理状况下的结果。两种药物在上述所有状况下均显示出非常有效，但在克罗恩病中依那西普似乎效果不佳。
两种药物都非常有效，尽管由于缺乏直接比较，无法对英夫利昔单抗和依那西普的疗效进行比较。
